StockMatusow.com Writers are:
Scott Matusow; Team Leader, owner and founder of StockMatusow.com.
Scott is an independent investor/writer/trader and team leader of StockMatusow.com.
He has have about fifteen years of stock market experience which include trading, investing, and managing his family’s trust as well as his personal account.
Scott has had the most success in trading/investing in smaller cap growth companies. Because Scott is not 'officially trained' in the markets, he see things 'outside the box.' Scott uses his ability to read situations and emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements. Using these allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis.
Scott has his own online talk show which can be heard at www.scottmatusow.com/radio .
During market hours, we engage in talk about Stocks and Politics. After hours, Scott engages in a variety of talk issues from Poker, Sports, Politics, Current Events and whatever the chat room people wish to talk about.
Other places you can follow Scott are:
Kyle Dennis; writer, analyst, trader, website design, and team member of Stockmatusow.com.
Kyle has a Biology degree from the University of California Los Angeles (UCLA) and specializes in trading the biotechnology sector.
Kyle has extensive experience in researching, writing, and editing articles that have been published in scientific journals. He uses these experiences to write and comment about the potential of various biotechnology companies. Kyle specializes in evaluating trial success, drug potential, and market valuations.
As an investor/trader, Kyle likes to focus on chart analysis and investor/trader sentiment to identify good entry and exit points.
Kyle can also be followed at www.twitter.com/kylewdennis @kylewdennis
Michael Kovar; writer, editor, investor, trader and team member of stockmatusow.com
Michael has spent over ten years in financial roles with companies large and small. Recently, he spent time in a consulting role with Thomson Reuters legal headquarters in Eagan, MN. He currently works in an analyst position with a healthcare organization. Since 2011, Michael has worked with Scott Matusow to help research and edit articles for Stockmatusow.com.
Michael can be followed at www.twitter.com/MMK_3399 @MMK_3399
Lowenthal Capital Partners (LCP) has joined Arrow Loop Research to deliver a value-based investing newsletter called Arrow Loop Research's Actionable Ideas for Maximizing Returns. Sign up for a free trial here.
LCP is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Boulder Law School.
Arrow Loop Research formed as a partnership between LCP, Dr. Paul Price, and Market Shadows (Paul is a managing partner of Market Shadows.)
Paul writes about stocks, options and the market every weekday on Real Money Pro, a subscription site on TheStreet.com. Paul has been a speaker at the International Traders Expo in New York City and the Options and Forex Expo in Las Vegas. He also gives investment seminars for subscribers of TheStreet's multiple subscription sites. Dr. Price is a featured contributor on Market Shadows.com, GuruFocus.com and TalkMarkets.com.
Paul followed his passion for the stock market when he gave up his career as a dentist to join Merrill Lynch back in April of 1987. Paul feels that he is “living the dream” of many investors. He stopped “going to work” when he turned 50 (in the year 2000) and has been living well from his investment returns ever since.
Paul enjoys sharing the accumulated market wisdom he’s gained from years in the markets. He loves analyzing companies and picking individual stocks. According to Paul, once you know what equities to buy, option writing (selling covered calls and/or naked puts) just flows naturally. They serve as ways to impose investment discipline and create income while providing an extra margin of safety versus plain vanilla share ownership. Paul’s articles stand out for their unique graphics which are packed with information which distills our TMI (too much information) world into easy to understand, and actionable advice.
Dr. Jon Peddie is one of the pioneers of the graphics industry, and formed Jon Peddie Research (JPR) to provide customer intimate consulting and market forecasting services. Peddie lectures at numerous conferences on topics pertaining to graphics technology and the emerging trends in digital media technology. Recently named one of the most influential analysts, regularly advises investors in the GLG network, he is frequently quoted in trade and business publications, was the president of Siggraph Pioneers, and e is also the author of several books his most recent, The History of Visual Magic in Computers. http://www.jonpeddie.com/about
I am President of Sporting Advantage Inc. which markets a revolutionary basketball product I invented, now called the SKLZ RAPID FIRE basketball return system, and owner of Hudson and Affiliates which markets cost reduction services of my affiliates to medium size organizations with a hundred to several thousand employees. I passed CPA exam in May 1977 and practiced as a CPA for 10+ years. I have 35+ years experience as an entrepreneur, inventor, investor and published writer. Check out my website- www.shootANDstar.com to view videos of my SKLZ RAPID FIRE basketball return system and to get 15% OFF ALL SKLZ brand sports training products!
Dr. George S. Mack is an analyst, managing director and founder at BioDecade where he writes proprietary biotech stock research for clients. He also performs interviews with biotech analysts and biotech CEOs for publications, including The Life Sciences Report.
Mack has authored for Nature Biotechnology, Nature Medicine and the Journal of the National Cancer Institute. He has been a consulting analyst to Decision Resources, and he has been a major contributor to Buyside Magazine, Wall Street Research and Reuters-Multex where he helped develop products intended for institutional investors.
Dr. Mack is a graduate of the University of South Carolina in Columbia and the Medical University of South Carolina in Charleston.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector. I am a contributing writer at CNA Finance and cover emerging opportunities as well as breaking news events.
I have an undergraduate degree and a graduate degree in the field of Sociology and am a life long "student." I learned about investing through observation as my father invested my grandfather's small nest egg before I was born when grandpa died in 1958. Dad invested in Growth and Income companies so that Grandma would not run out of money and would have an income. When she died in 1978 she was worth nearly $1 million with about 60% of that being Philip Morris as it had outperformed everything else by a wide margin. At 17 I inherited about $9,000 and kept it invested and benefited from the dividends for spending money while in college and graduate school, then I had money for a downpayment on a house in my mid 20's and kept the rest invested. I was mainly buy and hold but wasn't a fan of the tobacco industry so weaned off the PM for cash needs and also bought other stocks, mainly pharmaceuticals. Up until this year I was mainly a buy and hold investor. I the past couple years I have become much more active in researching and managing my investments.
I love growth, especially with game changing companies like: NTCXF, ARTH and CLIR. I also have holdings in more traditional growth companies and ETFs--JNJ and TAN for instance.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
I am an active investor in IP-centric investments for 6 years. I specialize in high risk / high reward situations both public and private. It is important for investors to plan for all outcomes as the litigation surrounding the IP investment takes many twists and turns. Extracting profits and limiting exposure are the keys to success.
I hope to provide information and strategies, which both expert and novice IP investors can profit from.
Follow me on twitter for the latest updates in the IP space:
Bishop Research & Analytics delivers comprehensive investment analysis on small and mid-cap companies, equity research, market trends, and valuation models. Our professional research provides investment managers with in-depth insights, detailed research, and timely market intelligence to outperform the benchmark indices and gain the advantage of leading the markets.
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is an alias that I've used for years on Yahoo so I use it when I write on SA. I have gained a significant amount of knowledge regarding the stem cell sector over the years and have recently launched a premium service covering this exciting area.
Owner and operator of: www.biostockselite.com Have over 15 years of investment experience and interest is dedicated to small cap biotech stocks. Articles submitted to SeekingAlpha will also be posted to my aforementioned site.
Patent News. We publish all the latest insights about patents and patent cases and ways to make profits from trading/investing in these up and coming companies.
Feel free to contact with any questions.
We await your reply.
Executive in the high tech industry for more than 30 years with multiple Fortune 500 companies.
Instrumental in growing smaller companies ten fold or more. Led sales/marketing groups setting high standards of excellence and achievement. College degrees in several tech areas. Invested in the market successfully for 30 years. Now, acting as a management consultant.
Enjoy personal activities in sports, Avid reader, focused on history and finance. Blessed with good health, family, and spiritual foundation.
My firm provides investment products and solutions for institutions and individual investors. I take particular attention to small and mid-cap companies in emerging markets. I like to research and trade good ideas; both long and short; with other experienced traders.
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
I have been trading part time for the past 10 years, focusing on swing trades and identifying how different stocks will "inhale and exhale" through the market. My primary targets are in the $2-$10 range, averaging over 2 million shares traded daily, and looking for an upswing. My goal is to average 10% per month, but will hold on for the long run with stocks that I believe in.
Personal Investor following most sectors but with focus on tech and further focus on communication chip companies and Internet infrastructure....although my watch list has many companies from many sectors.
I have a Mech Eng honors degree with 35 years as a petroleum engineer/onsite operations manager/finance, forecasting and metrics manager. I was also section chairperson for Society of Petroleum Engineers so have a good feel for the oil production and transport industry. 26 of those years were with Shell (mostly TEOR in CA) and the last 9 years overseas (ME) with Oxy.
I saved and invested well so retired in 2014 at age 58 and invest mainly as a hobby as I have my retirement secured.
I only look at stocks that have the possibility to double over a twelve month period and stocks in which the risk/reward ratio payout is high. In addition I focus on swing trade opportunities.
I focus more on valuations and risk/reward metrics as opposed to what make companies tick.
I have been a professional investor for over 20 years and during the past several years an economics analyst and financial writer for capital.gr, the biggest economic news portal in Greece.
I have managed money from time to time and have also done some seed venture capital projects in the past.
I work in the medical and healthcare field so my focus is mainly on Biotech stocks. I try to find the next Celgene, the next Pharamcylics if possible.
Been a trader and investor for 13 years.
Love the game, and I hope you enjoy my articles on here.
Good luck with your investments and I look forward to all of your comments and suggestions.
Read more here
I am an active investor and trader for my own brokerage account. I enjoy the sport of the markets and the challenges it presents every day. I have been reading SEC filings for many years, and I have grown accustomed to the natural resource sector in particular, although I like special situations in almost every sector. The longer I am around the market, the more I am drawn to smaller, lesser known opportunities. I have some free time on my hands and decided to give blogging a chance. I hope you find my writing informative and valuable.
Karl Guttag has over 34 years of experience in integrated circuit architecture related to Graphics and Image Processors Digital Signal Processing (DSP), and memory architecture. For the last 12 years he has worked on integrated circuit backplanes for Liquid Crystal on Silicon (LCOS) displays. Over the last 34 years he has identified new market opportunities and integrated circuit architectures to serve those markets.
He is named inventor on about 145 issued U.S. Patents including key patents related graphics and imaging processors, graphics interface circuits, microprocessors, signal processing (DSP), Synchronous DRAMs, and Video Rams. Billions of dollars of yearly revenue have been attributed to products using these inventions. Mr. Guttag is the youngest person elected to The Fellow of Texas Instruments.
2013-Present Navdy, CTO; a start-up working on automotive displays
2012-Present KGOnTech, President; Patent Litigation Technical Expert
2003-2011 Syndiant, CTO and Founder; a maker of LCOS Microdisplays
2001-2002 Kagutech, President; Inventor and Patent Litigation Technical Expert
1998-2001 Silicon Display, CTO; Maker of LCOS devices for Head Mount Displays
1977-1999 Texas Instruments; TI Fellow (elected 1982)
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the premium subscription service "Tipping The Scale" (as seen below). An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Tipping the Scale members gain access to the TTS Portfolio Tracker. Here, members see what I am buying and selling the minute it happens, along with what I have owned, bought, and sold historically. These are just a few of the features on the TTS Portfolio Tracker.
Tipping The Scale is an equity research platform that uses a numeric scale instead of the traditional "Buy, Hold, Sell" to identify the best investment opportunities in the market. Stock coverage is determined by market catalyst, and every company goes through a vigorous test in 10 different categories. The higher the total score, the bigger the upside. In addition, Tipping the Scale also provides a number of portfolio strategies to hedge the volatility of the market and protect from downside.
Check out my instablog for more information on the popular research service Tipping the Scale, including performance information, benefits, and how it all works.
After 8/28/16, I will be writing no more than 4 substantive Instablogs per year. Those blogs will be published in March, June, September and December.
Those blogs will concentrate on matters relating to portfolio positioning.
I will be posting substantive comments to my last published Instablog.
I have not used, nor will I even contemplate using SA's Instablog service as free advertising to sell a subscription service.
I have never received any compensation for the posts published at my blog website or here at SeekingAlpha. I am simply passing on what I have learned as an investor over 4+ decades free of charge. In all of my 2000+ posts since early October 2008, the primary purpose was to provide a framework for rational and fact based investment decision making that will hopefully reduce the number of errors made. That goal has been accomplished for the very few investors who have some interest in receiving it.
My most basic investment strategy is to focus on income generating securities and then to invest the cash flow into more of the same, creating a compounding impact over a long period of time. I will invest in securities throughout the capital structure on a worldwide basis. I am now and have always been a cautious total return investor (income + capital appreciation). A focus on income generation simply means that income generation through interest or dividend payments is an important part of my total return objective. I am no longer in an asset accumulation mode. Capital preservation is more important than capital appreciation. Income generation is only one aspect of an objective evaluation of potential rewards balanced against potential risks. After several decades of "turtle" investing, which sometimes requires me to pull my head back into the shell and to cease foraging in stock land (e.g. 1999), I am now admittedly absurdly diversified due largely to one of my risk management techniques that limits my monetary exposure to the securities of a single company. My monetary exposure is largely dictated by a balancing of potential risks and rewards taking into consideration income generation and potential for capital appreciation. As a risk control trading technique and in furtherance of my capital preservation emphasis, I will frequently use the natural volatility of a security to gradually build up a position, selling the highest cost shares on price spikes and buying back those shares when the purchase is lower than my average cost per share usually by more than 5%. The general idea is to lower my average cost per share over time with tax efficient share dispositions, thereby increasing my dividend yield for the remaining shares. I have also been a practitioner of dynamic or tactical asset allocation that will be driven by my big picture views, including my Vix Asset Allocation Model, as well as my opinions about the relative risks and opportunities of various asset classes. I was born in 1951, and started to invest in stocks when I was 16. I am not a financial advisor, but simply an individual investor who has been managing my own money for my adult life starting when I was a teenager. All of my brokerage accounts are cash accounts. I have never bought stock on margin. I have not added money to any of these accounts since 1984 and have used those accounts to fund my annual IRA contributions. I started my web site, Stocks & Politics, in October 2008 to do whatever I can to help individuals become better investors, which requires a lot of hard work and effort. After over 2000+ blogs, mostly long ones, I came to a realization that my time consuming and laborious efforts have been mostly futile and have been rewarded at best with faint praise. I will no longer be posting there. I would still emphasize that it is important for individuals to become as knowledgeable as possible before making any decision, with every individual taking full responsibility for their investment decisions and to prepare accordingly, which is what I try to do. The Twitter Generation will need IMO far greater investment skills than previous generations given what I now perceived about future U.S. economic conditions.